Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caro, J. J.
Right arrow Articles by Kelley, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caro, J. J.
Right arrow Articles by Kelley, H. E.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Health policy and outcome research
Right arrow Acute Cerebral Infarction
Right arrow Neuroprotectors

(Stroke. 2001;32:100.)
© 2001 American Heart Association, Inc.


Original Contributions

Predicting Treatment Costs After Acute Ischemic Stroke on the Basis of Patient Characteristics at Presentation and Early Dysfunction

J. Jaime Caro, MDCM; Krista F. Huybrechts, MS; Heather E. Kelley, MA for the Stroke Economic Analysis Group1

From Caro Research, Concord, Mass (J.J.C., K.F.H., H.E.K.); and the Division of General Internal Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada (J.J.C.).

Correspondence to J. Jaime Caro, Caro Research, 336 Baker Ave, Concord, MA 01742. E-mail jcaro{at}caroresearch.com

Background—Given the pressure on healthcare budgets, assessing the cost of managing a disease has become a major research focus; yet collection of these data are labor intensive and difficult. Understanding the predictors of cost provides an efficient means of incorporating such information in decision-making concerning new therapies.

Methods—Data from two 12-week multinational trials that collected information on a variety of neurological, functional, and cost parameters for 1341 ischemic stroke patients were examined by means of multiple linear regression. Because the intent is for the model to be predictive, only patient characteristics that can be known at the time of patient presentation or shortly thereafter were evaluated for inclusion in the model.

Results—The Barthel Index was the strongest predictor of cost in all models evaluated. Other major predictors, either directly or through their impact on survival, were stroke subtype, neurological impairment, congestive heart failure, and country. A good model fit was obtained, judging by the model statistics (model F=84, 3 df, P<0.0001) and the accuracy of the predictions (<3% difference between mean actual and predicted cost).

Conclusions—Through the use of key patient characteristics, this regression model allows for prediction of the cost of stroke care, which may be helpful in the context of therapeutic decisions and budgetary planning purposes. It also provides insight into how specific treatments, through their impact on clinical characteristics, can modify the cost of stroke treatment.


Key Words: outcome • statistical models • stroke • stroke management




This article has been cited by other articles:


Home page
StrokeHome page
R. Luengo-Fernandez, A. M. Gray, and P. M. Rothwell
Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature
Stroke, February 1, 2009; 40(2): e18 - e23.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. J. Hankey, J. Spiesser, Z. Hakimi, P. Carita, and S. Gabriel
Time frame and predictors of recovery from disability following recurrent ischemic stroke
Neurology, January 16, 2007; 68(3): 202 - 205.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. Luengo-Fernandez, A. M. Gray, and P. M. Rothwell
Population-Based Study of Determinants of Initial Secondary Care Costs of Acute Stroke in the United Kingdom
Stroke, October 1, 2006; 37(10): 2579 - 2587.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
G. Saposnik, F. Webster, C. O'Callaghan, and V. Hachinski
Optimizing Discharge Planning: Clinical Predictors of Longer Stay After Recombinant Tissue Plasminogen Activator for Acute Stroke
Stroke, January 1, 2005; 36(1): 147 - 150.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Rundek, K. Nielsen, S. Phillips, K. C. Johnston, M. Hux, D. Watson, and for the GAIN Americas Investigators
Health Care Resource Use After Acute Stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas Trial
Stroke, June 1, 2004; 35(6): 1368 - 1374.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K.-C. Chang, M.-C. Tseng, H.-H. Weng, Y.-H. Lin, C.-W. Liou, and T.-Y. Tan
Prediction of Length of Stay of First-Ever Ischemic Stroke
Stroke, November 1, 2002; 33(11): 2670 - 2674.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. Evans, F. Harraf, N. Donaldson, and L. Kalra
Randomized Controlled Study of Stroke Unit Care Versus Stroke Team Care in Different Stroke Subtypes
Stroke, February 1, 2002; 33(2): 449 - 455.
[Abstract] [Full Text] [PDF]